Hematologic parameters
. | PT, s . | . | APTT, s . | . | ||
|---|---|---|---|---|---|---|
| Group . | Average . | SD . | Average . | SD . | ||
| Control | 7.6 | 1.0 | 27.9 | 10.7 | ||
| Hemophilia control | 8.1 | 3.2 | 35.1 | 9.9 | ||
| Hemophilia/rFVIIa, 1 mg/kg | 6.2 | 2.5 | 30.1 | 7.3 | ||
| Hemophilia/rFVIIa, 3 mg/kg | 5.6 | 1.5 | 13.9*** vs B | 4.6 | ||
| Hemophilia/rFVIIa, 6 mg/kg | 6.4 | 2.3 | 18.5 | 9.5 | ||
| Hemophilia/rFVIIa, 10 mg/kg | 4.2** vs B | 14.3* vs B | 5.2 | |||
| Hemophilia/FVIIaIIa, 1 mg/kg | 7.0 | 0.1 | 20.3* vs B | 5.7 | ||
| Hemophilia/FVIIaIIa, 3 mg/kg | 7.0 | 14.6* vs B | 2.1 | |||
| Hemophilia/K337A-FVIIaIIa, 1 mg/kg | 7.4 | 16.2 | 2.6 | |||
| Hemophilia/K337A-FVIIaIIa, 3 mg/kg | 7.2 | 0.3 | 12.6*** vs B | 0.6 | ||
| Hemophilia/M298Q-FVIIa, 1 mg/kg | 6.6 | 1.1 | 18.6** vs B | 6.2 | ||
| Hemophilia/M298Q-FVIIa, 3 mg/kg | 6.4 | 1.5 | 14.1*** vs B | 7.8 | ||
. | PT, s . | . | APTT, s . | . | ||
|---|---|---|---|---|---|---|
| Group . | Average . | SD . | Average . | SD . | ||
| Control | 7.6 | 1.0 | 27.9 | 10.7 | ||
| Hemophilia control | 8.1 | 3.2 | 35.1 | 9.9 | ||
| Hemophilia/rFVIIa, 1 mg/kg | 6.2 | 2.5 | 30.1 | 7.3 | ||
| Hemophilia/rFVIIa, 3 mg/kg | 5.6 | 1.5 | 13.9*** vs B | 4.6 | ||
| Hemophilia/rFVIIa, 6 mg/kg | 6.4 | 2.3 | 18.5 | 9.5 | ||
| Hemophilia/rFVIIa, 10 mg/kg | 4.2** vs B | 14.3* vs B | 5.2 | |||
| Hemophilia/FVIIaIIa, 1 mg/kg | 7.0 | 0.1 | 20.3* vs B | 5.7 | ||
| Hemophilia/FVIIaIIa, 3 mg/kg | 7.0 | 14.6* vs B | 2.1 | |||
| Hemophilia/K337A-FVIIaIIa, 1 mg/kg | 7.4 | 16.2 | 2.6 | |||
| Hemophilia/K337A-FVIIaIIa, 3 mg/kg | 7.2 | 0.3 | 12.6*** vs B | 0.6 | ||
| Hemophilia/M298Q-FVIIa, 1 mg/kg | 6.6 | 1.1 | 18.6** vs B | 6.2 | ||
| Hemophilia/M298Q-FVIIa, 3 mg/kg | 6.4 | 1.5 | 14.1*** vs B | 7.8 | ||
Prothrombin time (PT) and activated partial thromboplastin time (APTT): Statistical significance was tested using a nonparametric test, the Kruskal-Wallis test. In case of overall P < .05, it was followed by Dunn posttest comparing all groups to the hemophilia control group. The PT was significantly decreased (**P < .01) after administration of 10 mg/kg rFVIIa at termination of the study. In all other groups the PT was 6-8 seconds with no significant differences between the groups. There were no differences in the APTT between the normal control, hemophilia control, and the hemophilia group dosed 1 mg/kg rFVIIa. In all other groups APTT was decreased, even significantly compared with the hemophilia control group in the following groups: 3 mg/kg rFVIIa (***P < .001), 10 mg/kg rFVIIa (*P < .05), 1 and 3 mg/kg FVIIaIIa (P < .05), 3 mg/kg K337A-FVIIaIIa (P < .001), 1 mg/kg M298Q-FVIIa (P < .001), and 3 mg/kg M298Q-FVIIa (P < .0001).